SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company.
- Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company.
- Spero, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States.
- The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.
- On March 31, 2022, Spero issued a press release announcing the Company’s fourth quarter and full year 2021 financial results.